BRD7抗体—艾普蒂

The bromodomain-containing protein 7 (BRD7) is a chromatin reader that binds acetylated lysine residues on histones, playing roles in transcriptional regulation, chromatin remodeling, and cellular processes such as differentiation and apoptosis. BRD7 is implicated in tumor suppression, with studies linking its dysfunction to cancers (e.g., breast, glioblastoma) and other diseases. Antibodies targeting BRD7 are critical tools for investigating its expression, localization, and molecular interactions. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study BRD7's involvement in pathways such as p53 signaling or its association with chromatin-modifying complexes like SWI/SNF. Commercial BRD7 antibodies are typically raised against specific epitopes (e.g., N-terminal regions) and validated for species reactivity (human, mouse). However, variability in antibody performance across studies highlights the need for rigorous validation, as non-specific binding or batch inconsistencies can affect reproducibility. Recent research also explores BRD7's role in non-cancer contexts, such as viral infection and neurodegenerative disorders, further driving demand for reliable antibodies to dissect its diverse functions.